Author/Editor		Podbregar, Matej; Černelč, Peter
Title		Zapleti in zdravljenje bolnikov z esencialno trombocitemijo
Translated title		Complications and treatment of essential thrombocythemia
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 68, št. 6
Publication year		1999
Volume		str. 353-6
Language		slo
Abstract		Background. Essential thrombocythemia (b'T) is a chronic myeloproliferative disorders. Bleeding and thrombotic complications are the major causes of morbidity and mortality in the patients with thrombocythemia. The incidence of these hemostatic complications is unknown. Patients. To determine the incidence of hemostatic complications and the prophylactic role of acetylsalicylic acid in the treatment of ET we analysed 124 patients with ET treated at the Department of Haematology, from January 1989 to December 1997. The age of patients with ET ranged from IS to 87 years (mean 57. 7 years). The patients were followed up for a total of 310 years. Results. The average platelet count of patients with ET was 986.3+-476.2x10 9/L. Women showed a statistically significant correlation between platelet count and platelet function studies with 1O micromol/LADP(r=-0.373,p=0.019). Thrombembolic complications and haemorrhage were noticed in 31 of the 124 patients (25.0%). There were significantly more complications in 17 (18.9%) females than 14 (41.2%) males (p =0.09). At the time ET was established there were 14 complications in 13 male and 14 complications in 14 female (p < 0.04). During observation and treatment there were only 10 complicatiorcs, 5 in (5.5%) females and 5 (14.7%) males (p=0.25). There was no correlation between the incidence or type of complications and gender, age, platelet count, platelet function studies and type of treatment. Conclusions. The incidence of thrombotic and haemorrhagic complication in ET is not negligible, there for it needs treatment.
Summary		Izhodišča. Esencialna trombocitemija (ET) je kronična mieloproliferativna bolezen, za katero jeznačilna nagnjenost h krvavitvam in trombozam. Pogostnost zapletov je po podatkih v literaturi različna. S pregledom naših bolnikov z ET smo želeli ugotoviti pogostnost zapletov in pomen zdravljenja terprofilaktičnega jemanja acetilsalicilne kisline. Bolniki. Od januarja 1989 do decembra 1997 smo na Kliničnem oddelku za hematologijo ugotovili ET pri 124 bolnikih (90 žensk in 34 moških). Starost bolnikov je bila od 18 do 87 let, mediana 57,5 leta. Bolnike smo opazovali skupno 310 let. Rezultati. Ob ugotovitvi bolezni je bilo pri 124 bolnikih z ET povprečno število trombocitov v krvi 986.3+-476,2X10 9/L. Le pri ženskah smo ugotovili statistično pomembno povezanost med številom trombocitov in pogostnostjo nastanka tromboctnih agregatov po dodatku10 mikromol/L ADP (r = -0,373, p = 0,019). Trombembolične zaplete in krvavitve smo ugotovili pri 31 od 124 (25 0%) bolnikov z ET, od tega pri 17 (18,9%) ženskah in pri 14 (41,2%) moških. Razlika med številom zapletov pri ženskah in moških ni bila statistično pomembna (p = 0, 09). Ob ugotovitvi bolezni je imelo 14 žensk 14 zapletov in 13 moških prav tako 14 zapletov (p < 0, 04). Med opazovanjem in zdravljenjem smo ugotovili le 10 zapletov, od tega 5 (5,5%) pri ženskah in 5 (14,7%) pri moških (p = 0,25). Povezanosti med vrsto zapleta, spolom, starostjo, številom trombocitov, izsledki preskusa agregacije trombocitov, zdravljenjem in pojavom zapletov nismo potrdili. Zaključki. Ker število zapletov pri bolnikih z ET ni majhno, priporočamo zdravljenje zvečanega števila trombocitov in profitlakso z acetilsalicilno kislino.
Descriptors		THROMBOCYTHEMIA, HEMORRHAGIC PLATELET COUNT THROMBOEMBOLISM CHEMOPREVENTION ASPIRIN HEMORRHAGE MYOCARDIAL INFARCTION